InterPAD - DETAILS

912445-05-7, Veliparib dihydrochloride, ABT-888, Veliparib hydrochloride, Veliparib (dihydrochloride), ABT-888 dihydrochloride, ABT888, (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide dihydrochloride, 912445-05-7 (HCl), Veliparib (ABT-888), 2-[(2R)-2-methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide, dihydrochloride, NSC-737664, ABT 888 dihydrochloride, Veliparib 2HCl, ABT888 hydrochloride, (R)-2-(2-Methylpyrrolidin-2-yl)-1H-benimidazole-4-carboxamide dihydrochloride (VELIPARIB), A 861695 dihydrochloride, ABT-888 HCl, Veliparib 2HCl; ABT-888, SCHEMBL2368883, SCHEMBL19328639, DTXSID30670432, HMS3295I11, HMS3426E03, AMY24139, BCP09427, EX-A2823, MFCD12407402, AKOS030231611, CS-0077, SB16479, 2-((2r)-2-methyl-2-pyrrolidinyl)-1h-benzimidazole-4-carboxamide dihydrochloride, AC-30346, AS-17023, HY-10130, DB-078941, A854345, J-505212, Veliparib dihydrochloride; ABT-888 dihydrochloride, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide--hydrogen chloride (1/2), 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-7-carboxamide dihydrochloride

No.	Title	Href
1	Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells. J Nutr Biochem. 2015 Dec;26(12):1442-7. doi: 10.1016/j.jnutbio.2015.07.015.	`Click`

No.

Title

Href

Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells. J Nutr Biochem. 2015 Dec;26(12):1442-7. doi: 10.1016/j.jnutbio.2015.07.015.

Click

Name	ABT-888
PubChem CID	45480520
Molecular Weight	317.21g/mol
Synonyms	912445-05-7, Veliparib dihydrochloride, ABT-888, Veliparib hydrochloride, Veliparib (dihydrochloride), ABT-888 dihydrochloride, ABT888, (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide dihydrochloride, 912445-05-7 (HCl), Veliparib (ABT-888), 2-[(2R)-2-methyl-2-pyrrolidinyl]-1H-benzimidazole-7-carboxamide, dihydrochloride, NSC-737664, ABT 888 dihydrochloride, Veliparib 2HCl, ABT888 hydrochloride, (R)-2-(2-Methylpyrrolidin-2-yl)-1H-benimidazole-4-carboxamide dihydrochloride (VELIPARIB), A 861695 dihydrochloride, ABT-888 HCl, Veliparib 2HCl; ABT-888, SCHEMBL2368883, SCHEMBL19328639, DTXSID30670432, HMS3295I11, HMS3426E03, AMY24139, BCP09427, EX-A2823, MFCD12407402, AKOS030231611, CS-0077, SB16479, 2-((2r)-2-methyl-2-pyrrolidinyl)-1h-benzimidazole-4-carboxamide dihydrochloride, AC-30346, AS-17023, HY-10130, DB-078941, A854345, J-505212, Veliparib dihydrochloride; ABT-888 dihydrochloride, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4- carboxamide, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide--hydrogen chloride (1/2), 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide;dihydrochloride, 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-7-carboxamide dihydrochloride
Drug Type	Small molecule
Formula	C₁₃H₁₈Cl₂N₄O
SMILES	CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl
InChI	1S/C13H16N4O.2ClH/c1-13(6-3-7-15-13)12-16-9-5-2-4-8(11(14)18)10(9)17-12;;/h2,4-5,15H,3,6-7H2,1H3,(H2,14,18)(H,16,17);2*1H/t13-;;/m1../s1
InChIKey	DSBSVDCHFMEYBX-FFXKMJQXSA-N
CAS Number	912445-05-7
TTD ID	D0Q7UD
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Curcumin, ABT-888
Partner Name	Curcumin
Disease Info	[ICD-11:2B5Y]	Malignant mesenchymal neoplasm		Investigative
Biological Phenomena	Inhibition-->Homologous recombination
Gene Regulation	Up-regulation	Expression	H2AX	hsa3014
Gene Regulation	Down-regulation	Expression	RAD51	hsa5888
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	U2OS	Osteosarcoma	Homo sapiens (Human)	CVCL_0042
In Vivo Model	2×10⁶ human MDA-MB-231 cells were prepared with 200 uL of PBS/matrigel gel (1:1 ratio) and injected subcutaneously into the flanks of athymic nude mice (two-site injections).
Result	Our study indicates that cotreatment of curcumin and PARP inhibitor might be useful for the combination chemotherapy for aggressive breast cancer treatment as a natural bioactive compound.